SCHEMBL12355698

SCHEMBL12355698

CCCC1Cc2cccc([N+](=O)[O-])c2C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40
TDP1 Q9NUW8 2/20 0.40
FYN P06241 1/20 0.39
ALDH1A1 P00352 3/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ACHE P22303 1/20 0.37
TSHR P16473 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
DRD2 P14416 2/20 0.36
GPR35 Q9HC97 1/20 0.36
S100A4 P26447 1/20 0.36
HSD17B10 Q99714 2/20 0.36
ALOX15 P16050 2/20 0.36
CYP3A4 P08684 1/20 0.36
ADRA2C P18825 1/20 0.35
NPY1R P25929 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2246781 0.82 GPR35 (0.42) CHRNB2CHRNA4TDP1ALDH1A1MAPT
SCHEMBL2242996 0.80 CHRNB2 (0.35) CHRNB2CHRNA4TDP1ALDH1A1MAPT
SCHEMBL12716705 0.80 CHRNB2 (0.39) CHRNB2CHRNA4TDP1ALDH1A1MAPT
SCHEMBL1415461 0.78 MTNR1A (0.47) CHRNB2CHRNA4TDP1ALDH1A1MAPT
Ammonia Solution, Strong SCHEMBL4418079 0.73 MAPT (0.45) CHRNB2CHRNA4TDP1ALDH1A1MAPT
SCHEMBL5916971 0.73 GPR35 (0.46) CHRNB2CHRNA4TDP1ALDH1A1MAPT
SCHEMBL11444096 0.73 TDP1 (0.42) CHRNB2CHRNA4TDP1ALDH1A1MAPT
SCHEMBL12355694 0.73 PNMT (0.57) FYNADRA2C
SCHEMBL7909196 0.73 ACHE (0.42) CHRNB2CHRNA4TDP1ALDH1A1MAPT
SCHEMBL7517485 0.72 TDP1 (0.41) CHRNB2CHRNA4TDP1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989451-B2 Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments AUCKLAND UNISERVICES LIMITED (NZ) 2011-08-02 US disclosed